Pharmaceutical

Immortagen, Inc. announced that it has successfully completed its Series A financing.  Immortagen is a cutting edge cancer company that is developing genetic analysis tools for personalized medicine.  These proprietary tools will assist pharmaceutical and diagnostics companies to interpret next-generation genetic data and guide clinical trial design and recruitment.  Immortagen’s product pipeline fills a key gap as more …

Immortagen, Inc. announced that it has successfully completed its Series A financing. Immortagen is a cutting edge cancer company that is developing genetic analysis tools for personalized medicine. These proprietary tools will assist pharmaceutical and diagnostics companies to interpret next-generation genetic data and guide clinical trial design and recruitment. Immortagen’s product pipeline fills a key gap as more and more patient tumors are sequenced, and genetic analysis of the data is required. Founded by a team of leading physician-researchers and complemented with proven management, Immortagen believes it will fill a key gap in the global oncology market.
Related Files


ImmortaPressFinl for Series A 8-1-16-1-2.docx
This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immortagen-inc-completes-series-a-financing-for-personalized-medicine-300330524.html
SOURCE Immortagen, Inc.

MARKETS

Markets
TSX18861.36-217.28
TSXV617.26-9.08
DOW30775.43-253.88
S&P 5003785.38-33.45
NASD11028.74-149.16
ASX6568.10-132.10

COMMODITIES

Commodities
Gold1794.03-12.85
Silver19.81-0.45
Copper3.57-0.14
Palladium1908.50-13.50
Platinum889.00-8.00
Oil106.94+1.18
Heating Oil3.95+0.12
Natural Gas5.74+0.31

DOWNLOAD FREE REPORTS

×